Research Radartracking 1 published studies · 1 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Sulforaphane

Cruciferous ITC: NRF2/HDAC/DNMT ↑/↓, CSC ↓; strong PD in prostate/bladder/colorectal/breast.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🏥⭐⭐⭐⭐ Strong — Multiple human trials with PD and some clinical endpoints; robust mechanistic base.SFNBroccoli sprout extract

Forms: Broccoli sprout extract capsules (20-50 mg SFN glucoraphanin + myrosinase) · Fresh sprouts (50-100 g/day)

Educational only, not medical advice. OncoForge makes no claim that Sulforaphane treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Isothiocyanate from broccoli sprouts that activates NRF2 detox defenses, inhibits HDAC/DNMT to re-express tumor suppressors, and targets cancer stem-cell traits; multiple human trials show pharmacodynamic and clinical signals (esp. prostate/bladder).

Evidence at a glance

Tier 4 · clinicalProstateBladderColorectalBreast

Phase II prostate PSA (TRAP); bladder recurrence HR 0.4; NRF2/HDAC PD robust; meta-CSC signals; ongoing CRC/breast trials.

How it may work

Sulforaphane (SFN) modifies Keap1 cysteines, stabilizing NRF2 and inducing HO-1, NQO1, GCLC, and phase II enzymes; it also inhibits class I/II HDACs and DNMTs, restoring p21 and other suppressors. SFN reduces CSC self-renewal (ALDH+/CD44+↓), impairs EMT, and sensitizes tumors to chemo/radiation. Clinical studies show PSA kinetics and tissue HDAC suppression in prostate, and reduced bladder cancer recurrence signals with broccoli sprout extracts.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

  • NRF2↑Keap1 modification for detox induction
  • HDAC↓Histone acetylation increase
  • DNMT↓Promoter demethylation
  • CSC↓ALDH/CD44 reduction
  • EMT↓Self-renewal impairment
NRF2HDACDNMTCSC

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Overlapping mechanisms

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories
Gi UpsetThyroid CautionTki Interaction
Potential interactions
  • TKIsMonitorLowTheoreticalCYP1A2 induction potential.
  • chemoSynergizeLowTheoreticalSensitization without antagonism.
  • CisplatinSynergizeLowTheoreticalEfficacy boost in bladder cancer.

Timing

References

Research

No published studies for Sulforaphane yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Sulforaphane depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 20–100 mg/day SFN equivalents (po) divided BID; with myrosinase source, Trials 50-100 mg glucoraphanin/day; fresh sprouts ~30 mg SFN/100g; stable formulations essential..

Trials studying Sulforaphane

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar